Latest Insider Transactions at Ikena Oncology, Inc. (IKNA)
This section provides a real-time view of insider transactions for Ikena Oncology, Inc. (IKNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Ikena Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Ikena Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 04
2023
|
Orbimed Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
153,121
+6.37%
|
-
|
|
Aug 04
2023
|
David P Bonita |
BUY
Grant, award, or other acquisition
|
Indirect |
153,121
+6.37%
|
-
|
|
Jun 24
2022
|
David P Bonita |
SELL
Open market or private purchase
|
Indirect |
162,000
-3.78%
|
$648,000
$4.87 P/Share
|
|
Jun 24
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private purchase
|
Indirect |
162,000
-3.78%
|
$648,000
$4.87 P/Share
|
|
Jun 23
2022
|
David P Bonita |
SELL
Open market or private purchase
|
Indirect |
23,419
-1.2%
|
$70,257
$3.71 P/Share
|
|
Jun 23
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private purchase
|
Indirect |
23,419
-1.2%
|
$70,257
$3.71 P/Share
|
|
Jun 22
2022
|
David P Bonita |
SELL
Open market or private purchase
|
Indirect |
66,806
-3.37%
|
$200,418
$3.55 P/Share
|
|
Jun 22
2022
|
Orbimed Advisors LLC Director |
SELL
Open market or private purchase
|
Indirect |
66,806
-3.37%
|
$200,418
$3.55 P/Share
|
|
Jan 18
2022
|
Maude Tessier Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,786
+21.71%
|
$215,358
$3.87 P/Share
|
|
Jan 11
2022
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
964
-2.12%
|
$11,568
$12.0 P/Share
|
|
Jan 11
2022
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
964
+2.08%
|
$1,928
$2.15 P/Share
|
|
Jan 10
2022
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
36
-0.08%
|
$432
$12.0 P/Share
|
|
Jan 10
2022
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36
+0.08%
|
$72
$2.15 P/Share
|
|
Dec 14
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,959
-0.48%
|
$83,426
$14.0 P/Share
|
|
Dec 14
2021
|
Jean Francois Formela |
SELL
Open market or private sale
|
Indirect |
5,959
-0.48%
|
$83,426
$14.0 P/Share
|
|
Dec 13
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
8,330
-0.66%
|
$116,620
$14.64 P/Share
|
|
Dec 13
2021
|
Jean Francois Formela |
SELL
Open market or private sale
|
Indirect |
8,330
-0.66%
|
$116,620
$14.64 P/Share
|
|
Dec 10
2021
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,000
-2.2%
|
$14,000
$14.76 P/Share
|
|
Dec 10
2021
|
Xiaoyan Michelle Zhang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+2.15%
|
$2,000
$2.15 P/Share
|
|
Dec 10
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
11,989
-0.95%
|
$179,835
$15.03 P/Share
|
|
Dec 10
2021
|
Jean Francois Formela |
SELL
Open market or private sale
|
Indirect |
11,989
-0.95%
|
$179,835
$15.03 P/Share
|
|
Mar 30
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
125,000
+12.5%
|
$2,000,000
$16.0 P/Share
|
|
Mar 30
2021
|
Jean Francois Formela |
BUY
Open market or private purchase
|
Indirect |
125,000
+12.5%
|
$2,000,000
$16.0 P/Share
|
|
Mar 30
2021
|
David P Bonita |
BUY
Conversion of derivative security
|
Indirect |
5,214,394
+50.0%
|
-
|
|
Mar 30
2021
|
David P Bonita |
BUY
Open market or private purchase
|
Indirect |
423,400
+21.9%
|
$6,774,400
$16.0 P/Share
|
|
Mar 30
2021
|
David P Bonita |
BUY
Conversion of derivative security
|
Indirect |
1,885,403
+50.0%
|
-
|
|
Mar 30
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,750,361
+48.81%
|
-
|
|
Mar 30
2021
|
Otello Stampacchia |
BUY
Grant, award, or other acquisition
|
Indirect |
450,000
+16.67%
|
$7,200,000
$16.0 P/Share
|
|
Mar 30
2021
|
Otello Stampacchia |
BUY
Conversion of derivative security
|
Indirect |
1,799,123
+50.0%
|
-
|
|
Mar 30
2021
|
Jean Francois Formela |
BUY
Conversion of derivative security
|
Indirect |
4,750,361
+48.81%
|
-
|
|
Mar 30
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
5,214,394
+50.0%
|
-
|
|
Mar 30
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
423,400
+21.9%
|
$6,774,400
$16.0 P/Share
|
|
Mar 30
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,885,403
+50.0%
|
-
|